Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech Inc. has demonstrated strong revenue growth, with surgical soft tissue repair product sales increasing by 24% year-over-year, reaching $23.4 million, alongside a positive trajectory for other product lines such as bone fusion products. The company is poised for continued growth with an anticipated revenue increase of 13-17% for 2026, following a 3-5% growth in 2025, and has recently achieved profitability in its continuing operations as of the third quarter of 2025. Additionally, the securing of a contract with Vizient, the largest group purchasing organization in the U.S., is expected to further enhance Sanara's market access and bolster revenue streams through expanded sales of its products at pre-negotiated terms.

Bears say

Sanara MedTech Inc. reported net revenue of $26.3 million, reflecting a year-over-year growth of 21.5%, which was slightly below projected figures, raising concerns about revenue generation capabilities. The company's outlook is hindered by several risks, including the potential for lower-than-expected revenue growth, challenges in acquiring new customers, and difficulties in launching new products and services. Furthermore, a significant reduction in the EV/Revenue multiple from 4.3x to 3.0x suggests a reassessment of the company’s market valuation following the exclusion of telehealth from its business model.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.